QCG
RNAM

Quadrant Capital Group’s Avidity Biosciences RNAM Stock Holding History

Quadrant Capital Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,196
Closed -$231K – 2794
2025
Q4 		$231K Buy
3,196
+3
+0.1% +$194 0.01% 1253
2025
Q3 		$139K Buy
+3,193
New +$129K ﹤0.01% 1384
2025
Q2 		– Sell
-3,171
Closed -$93.6K – 2332
2025
Q1 		$93.6K Sell
3,171
-9
-0.3% -$280 ﹤0.01% 1539
2024
Q4 		$92.5K Sell
3,180
-59
-2% -$2.47K 0.01% 1094
2024
Q3 		$149K Sell
3,239
-69
-2% -$2.99K 0.01% 847
2024
Q2 		$135K Hold
3,308
– – 0.01% 840
2024
Q1 		$84.4K Hold
3,308
– – 0.01% 1102
2023
Q4 		$29.9K Buy
3,308
+2,714
+457% +$18.1K ﹤0.01% 1637
2023
Q3 		$3.79K Buy
+594
New +$5.12K ﹤0.01% 2241
2022
Q2 		– Sell
-29
Closed -$1K – 2700
2022
Q1 		$1K Buy
+29
New +$493 ﹤0.01% 2374

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Quadrant Capital Group's RNAM Position: Q1 2026 in Review

Quadrant Capital Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 3,196 shares — an estimated $231K sold.

Quadrant Capital Group first reported a position in RNAM in Q1 2022 and held it in 10 quarters. The position peaked at $231K in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Quadrant Capital Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 3,196 Avidity Biosciences shares in Q1 2026, an estimated $231K.
  • Quadrant Capital Group first reported a position in Avidity Biosciences in Q1 2022 and held it in 10 quarters.
  • Quadrant Capital Group's Avidity Biosciences position peaked at $231K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.